From Discovery to the Clinic
 TriLink has teamed up with Avecia to enable you to easily transition from R&D and pre-clinical studies to clinical trials and commercial manufacture of therapeutic oligonucleotides.
Working with this alliance minimizes your challenges and risks associated with transitioning from a research-grade vendor to an oligonucleotide development service and manufacturing company. We have harmonized our processes, so you can enjoy a smooth changeover when scaling up for clinical trials.
One choice for reliability and consistency
The common technology platform between TriLink and Avecia removes
potential
hurdles ensuring a worry-free transition from development through to the clinic.
Features |
Benefits |
| Common technology and analytical platforms |
Reduced risk of repeating pre-clinical investigations ahead of clinical trials |
| Common specifications |
Rapid pre-clinical to clinical transition |
Close communication between customer and alliance
|
Reduced risk of missing key deadlines |
Learn more about TriLink's Therapeutic Oligo Services
Read the press release about this program
Visit Avecia's website
|
